Carvedilol to prevent esophagus bleeding in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (long-term liver scarring).
- You are between 18 and 75 years old.
- You do not currently have esophageal or stomach varices (swollen veins).
- You must be able to safely take beta-blockers like carvedilol (no allergy or other contraindications).
- You have not had prior procedures for varices, like EVL or sclerotherapy.
- You have not had surgery for portal hypertension and do not have major heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding endoscopic banding helps prevent bleeding from enlarged varices in people with cirrhosis who still have high-risk varices despite taking carvedilol.
This trial tests whether a medicine called carvedilol can lower high blood pressure in the liver veins of people with cirrhosis. It uses a special ultrasound probe to measure the pressure before and after taking the medicine.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial tests if adding midodrine to carvedilol is better than carvedilol alone at preventing another bleed from varices in patients with cirrhosis who have had a high-risk variceal bleed.
This trial compares two approaches to prevent first-time bleeding from enlarged veins in the food pipe (varices) in people with liver cancer and cirrhosis. One group receives a daily pill (carvedilol), and the other receives the pill plus a procedure (endoscopic banding) to tie off the veins.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.